Darunavir
The Chinese authorities have indicated that Darunavir against 2019-nCoV may be successful. In vitro cell studies have shown that Darunavir can effectively inhibit replication of the new strain, at a concentration of 300 micromolar, according to preliminary research Darunavir, in conjunction with cobicistat, will be used in patients with COVID-19 pneumonia in trial number NCT04252274 [50]. Such a mixture is currently approved by the United States Food and Drug Administration (FDA) in AIDS treatment. Darunavir is another HIV protease inhibitor and cobicistat, like ritonavir, is a booster to enhance the pharmacokinetics and pharmacodynamics of darunavir by inhibiting cytochrome P450 (CYP3A) [53] [54]. Due to in vitro evidence that supports its ability to fight this infection, Darunavir is being studied as a potential cure for SARS-CoV-2, the coronavirus responsible for COVID-19[52]. Clinical trials are under progress and are scheduled to end in August 2020.Although, HIV-1 protease inhibitor is currently being evaluated in a clinical trial (NCT04252274), but no in vitro or human data exist to support its use against 2019-nCoV.